Vaneck Healthcare Trusector ETF (TRUH US)
TRUH US$31.34
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Share price activity
- Last (Price)
- 31.34
- Change
- ▲ 0.07 (0.22)
- Bid / Ask
- 31.31 - 31.38
- Volume
- 434
- Turnover
- 11,712
- Open
- 31.34
- Day Range
- 31.34 - 31.34
- VWAP
- 31.23
- Prev Close
- 31.27
- Last Trade
- 28/10 4:00pm
Fund profile
Fund size
$624,973
OCT 2026
Distributions
Quarterly
Since inception
0.6 yrs
APR 2026
- Legal name
- Vaneck Healthcare TruSector ETF
- Issuer
- VanEck
- Type
- Exchange-Traded Fund
- Structure
- Open Ended Investment Company
- Management style
- Actively managed
- Morningstar category
- Health
- Category index
- Morningstar US Health TR USD
- Benchmark
- N/A
- ETF net assets
- $624,973
- Units on issue
- 20,000
- Management fee
- 0.10% p.a.
- Domicile
- United States
- Base currency
- USD
- Inception
- 1 APR 2026
- Listed
- 2 APR 2026
Objective and strategy
The investment seeks long-term capital appreciation. The fund is an actively managed exchange-traded fund that seeks to achieve its investment objective by investing, under normal market circumstances, at least 80% of its total assets in equity securities of healthcare-related companies or instruments that provide exposure to healthcare-related companies as determined by the Adviser. For purposes of this policy, the term “assets” means net assets plus the amount of any borrowings for investment purposes. The fund is non-diversified.
Asset allocation
US equity 99.97%Non-US equity 0.00%
| Asset class | Net % | Long % | Short % |
|---|---|---|---|
| Equity | 99.97 | 99.97 | — |
| Bond | 0.00 | 0.00 | — |
| Cash | 0.03 | 0.03 | — |
| Other | 0.00 | 0.00 | — |
Sector exposure
Cyclical 0.00%Sensitive 0.00%Defensive 100.00%
- Basic Materials
- 0.00%
- Consumer Cyclical
- 0.00%
- Financial Services
- 0.00%
- Real Estate
- 0.00%
- Communication Services
- 0.00%
- Energy
- 0.00%
- Industrials
- 0.00%
- Technology
- 0.00%
- Consumer Defensive
- 0.00%
- Healthcare
- 100.00%
- Utilities
- 0.00%
Region exposure
Developed markets 100.00%Emerging markets 0.00%
- North America
- 100.00%
- Latin America
- 0.00%
- United Kingdom
- 0.00%
- Europe Developed
- 0.00%
- Europe Emerging
- 0.00%
- Africa / Middle East
- 0.00%
- Japan
- 0.00%
- Australasia
- 0.00%
- Asia Developed
- 0.00%
- Asia Emerging
- 0.00%
Country exposure
- United States
- 100.00%
Style box
- Style
- Large Value
- Average moat
- Wide
Size score
236
Value-growth score
49
Economic moat
Wide 62%Narrow 33%None 5%
Market capitalisation
- Giant
- 15.94%
- Large
- 60.39%
- Mid
- 21.97%
- Small
- 1.70%
- Micro
- 0.00%
Giant 16%Large 60%Mid 22%Small 2%
- Average market cap
- $212.46B
- Number of holdings
- 62
- Shares held
- 61
Portfolio statistics · 23 OCT 2026
- Price / earnings
- 29.92
- Price / book
- 4.72
- Price / sales
- 1.60
- Price / cash flow
- 17.76
- Dividend yield
- 1.56%
- Assets in top 10
- 60.60%
- Return on equity
- 28.19%
- Net margin
- 15.65%
- Earnings growth (3 yr)
- 12.71%
Top holdings · top 10 = 60.94% of assets
| Holding | % Weight | First bought | Market value | Currency | Units held | Sector | Country | |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | 15.27 | APR 2026 | 91,217 | USD | 77 | Healthcare | United States | |
| Johnson & Johnson JNJ | 10.44 | APR 2026 | 62,344 | USD | 233 | Healthcare | United States | |
| AbbVie Inc ABBV | 7.54 | APR 2026 | 45,023 | USD | 171 | Healthcare | United States | |
| Merck & Co Inc MRK | 5.95 | APR 2026 | 35,529 | USD | 238 | Healthcare | United States | |
| UnitedHealth Group Inc UNH | 5.46 | APR 2026 | 32,620 | USD | 87 | Healthcare | United States | |
| Thermo Fisher Scientific Inc TMO | 4.10 | APR 2026 | 24,466 | USD | 36 | Healthcare | United States | |
| Amgen Inc AMGN | 3.69 | APR 2026 | 22,029 | USD | 52 | Healthcare | United States | |
| Gilead Sciences Inc GILD | 3.04 | APR 2026 | 18,154 | USD | 120 | Healthcare | United States | |
| Abbott Laboratories ABT | 2.82 | APR 2026 | 16,859 | USD | 167 | Healthcare | United States | |
| Pfizer Inc PFE | 2.64 | APR 2026 | 15,796 | USD | 550 | Healthcare | United States |
Trailing returns · 30 SEP 2026
Fund (NAV) Market price
1M
-0.9
3M
6.1
| Period | Fund (NAV) % | Market price % | Before fees % | Rank in category |
|---|---|---|---|---|
| 1 month | -0.91 | -0.70 | — | 39 / 176 |
| 3 months | 6.12 | 6.46 | — | 34 / 175 |
Returns to 30 SEP 2026, periods of 3 years and longer annualised. Rank is the percentile in the Morningstar category at 30 SEP 2026 (1 = best) over the funds ranked.
Portfolio risk score
Risk score
54.5
Morningstar Portfolio Risk Score at 30 SEP 2026.
Fees and costs
- Management fees and costs
- 0.10% p.a.
- PDS dated
- 20 FEB 2026
Sustainability rating · 31 AUG 2026
High
ESG risk score
17.41
Category average 21.96
- Rank in category
- 12th percentile of 594 funds
- Environmental risk
- 2.30
- Social risk
- 10.77
- Governance risk
- 4.35
- Portfolio covered
- 100.0%
ESG risk of holdings
- Negligible
- 4.47%
- Low
- 66.38%
- Medium
- 29.15%
- High
- 0.00%
- Severe
- 0.00%
16.26% of assets are in companies with high or severe controversies.
Carbon · 31 AUG 2026
Carbon risk score
2.24
Category average 2.74
- Carbon risk
- Low Risk
- Fossil fuel involvement
- 0.00%
- Category average
- 0.16%
- Low Carbon Designation
- Yes
- Portfolio covered
- 100.0%
Fund managers
- David Schassler
- John Lau
Tenure
- Number of managers
- 2
- Average tenure
- 0.5 years
- Longest tenure
- 0.5 years
- Longest serving
- David Schassler, John Lau · since 1 APR 2026
- Most recent appointment
- David Schassler, John Lau · since 1 APR 2026
- Managed since
- 1 APR 2026
- Other funds managed
- 28
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.